Dr. David Ross Parkinson, M.D., has been the Chief Executive Officer and President of ESSA Pharma Inc. since January 7, 2016. Dr. Parkinson serves as an Acting Chief Executive Officer at Zyngenia, Inc. Dr. Parkinson has been Venture Advisor at New Enterprise Associates since 2016 and served as its Venture Partner since 2012 until 2016. He specializes on healthcare and biopharma. He served as an Interim Chief Medical Officer of Zyngenia, Inc. He served as the President and Chief Executive Officer of Nodality, Inc. from September 24, 2007 to 2012. Prior to October 2007, he served as Senior Vice President of Oncology Research & Development at Biogen Inc. since March 29, 2006. He served as a Vice President of Oncology Development & Commercialization of Amgen Inc. since August 4, 2005. He served as Vice President and Head of the Clinical Oncology Therapeutic Area of Amgen Inc. since May 21, 2003. He has previously led oncology clinical development activities at Novartis from 1997 to 2003, Amgen from 2003 to 2006 and Biogen Idec from 2006 to 2007. He directed global development efforts in oncology for all of Amgen's new product candidates and new indications for marketed products. Dr. Parkinson has a wealth of experience in drug development and an international reputation in clinical oncology, including a track record in developing new therapies in oncology. He joined Amgen from Novartis Pharmaceutical Corporation where he was Global Head, Translational Development and a member of their Oncology Business Unit Executive Committee. He served as Vice President of global clinical oncology development at Novartis Corporation. As head of oncology clinical research and development at Novartis, he led teams that successfully registered numerous important new therapies, including Gleevec(TM), the first successful protein kinase inhibitor and Zometa(R), a bisphosphonate indicated for the treatment of bone metastases. He serves as the Chairman of the Clinical Advisory Board and Director of Zyngenia, Inc. He has been an Independent Non-Executive Director at 3SBio Inc. since May 23, 2015. Dr. Parkinson has been a Director of Cerulean Pharma Inc. since October 29, 2014. He has been a Member of Scientific Advisory Board at Critical Outcome Technologies Inc. since March 23, 2015. He has been a Director of Threshold Pharmaceuticals Inc. since May 12, 2010. He has been a Director of CTI BioPharma Corp. since June 05, 2017. He has been a Director of ESSA Pharma Inc. since June 24, 2015. He serves as an Independent Director of Tocagen Inc. and DeNovo Biosciences, Inc. Dr. Parkinson serves as a Director of Myeloma Research Foundation. He serves as a Member of Scientific Advisory Board at Onconova Therapeutics, Inc. and served as its Member of Clinical Advisory Board until December 6, 2016. He served as a Member of Scientific Advisory Board at Mersana Therapeutics, Inc., since October 21, 2013. He served as a Director of Nodality, Inc. He is a member of the FDA's Science Board. He served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011, as a Board Director of the Ontario Institute for Cancer Research. Dr. Parkinson served as a Director of Ambit Biosciences Corporation from March 2013 to November 10, 2014. He served as a Director of the American Association of Cancer Research (AACR) from 2006 to 2009. He served as a Member of Clinical Advisory Board at CytRx Corporation since February 2008. He served as a Director of AbbVie Biotherapeutics Inc. (alternate name, Abbott Biotherapeutics Corp.) since December 2008. He served as the President of the International Society of Biological Therapy and past Editor of the Journal of Immunotherapy. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as the Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. Dr. Parkinson joined the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute, where he also served as a member of the Biologics Evaluation Committee at the U.S. Food and Drug Administration. His skills in drug evaluation brought him to the attention of Novartis, where he occupied positions of increasing responsibility since 1997. He is the recipient of numerous honors and awards, including the Wiley Medal (Commissioner''s Citation of Merit) from the U.S. Food and Drug Administration in 1997 and teaching awards at both Tufts University and the University of Texas. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center and has authored over 100 peer-reviewed publications. He is a recipient of the FDA's Cody Medal. Dr. Parkinson pursued clinical training at the Royal Victoria Hospital, McGill University and at the New England Medical Center, where he was also an Assistant Professor at Tufts University School of Medicine and an attending physician in hematology/oncology. He completed a Hematology Fellowship at Royal Victoria Hospital at McGill University in Montreal and was a Research Fellow at the New England Medical Center at Tufts University in Boston. He delivered the 12th Andrew H. Weinberg Memorial Lecture at the Harvard University School of Medicine in 2008. Dr. Parkinson received his M.D from the University of Toronto, Faculty of Medicine in 1977, with Internal Medicine.

 Oncology